Immunity to the respiratory pathogen Bordetella pertussis

Mucosal Immunology

Volumn 5, Issue 5, 2012, Pages 485-500

  Higgs, R ^a   Higgins, S C ^a   Ross, P J ^a   Mills, K H G ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE TOXIN; BACTERIAL PROTEIN; BACTERIAL TOXIN; BETA DEFENSIN 1; BETA DEFENSIN 2; BORDETELLA RESISTANCE TO KILLING A PROTEIN; COMPLEMENT; COMPLEMENT COMPONENT C4B BINDING PROTEIN; FILAMENTOUS HEMAGGLUTININ; GAMMA INTERFERON; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 23; LIPOOLIGOSACCHARIDE; PERTUSSIS TOXIN; PERTUSSIS VACCINE; POLYPEPTIDE ANTIBIOTIC AGENT; PROTEIN PRN; TRACHEAL CYTOTOXIN; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ANTIBODY SPECIFICITY; BACTERIAL IMMUNITY; BACTERIAL VIRULENCE; BORDETELLA PERTUSSIS; CELLULAR DISTRIBUTION; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE MODEL; EFFECTOR CELL; HOST PATHOGEN INTERACTION; HOST RESISTANCE; HUMAN; HUMORAL IMMUNITY; IMMUNOMODULATION; INNATE IMMUNITY; LUNG ALVEOLUS MACROPHAGE; LUNG INFILTRATE; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; PASSIVE IMMUNIZATION; PERTUSSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY T LYMPHOCYTE; REVIEW; TH1 CELL; TH17 CELL; TH2 CELL; TYPE III SECRETION SYSTEM;

EID: 84865386529     PISSN: 19330219     EISSN: 19353456     Source Type: Journal    
DOI: 10.1038/mi.2012.54     Document Type: Review

References (187)

1. Black, R. E. et al. Global, regional, and national causes of child mortality in 2008: A systematic analysis. Lancet 375, 1969-1987 (2010
2. Cherry, J. D. The present and future control of pertussis. Clin. Infect. Dis. 51, 663-667 (2010
3. Centers for Disease, C. & Prevention. Notes from the fi eld: Pertussis-California, January-June 2010. MMWR Morb. Mortal. Wkly. Rep. 59, 817 (2010
4. Barret, A. S. et al. Pertussis outbreak in northwest Ireland, January-June 2010. Euro Surveill. 15, pii=19654 (2010
5. Roper, K. Outbreak of pertussis, 1 January to 31 March 2009. Commun. Dis. Intell. 33, 36-37 (2009
6. Octavia, S. et al. Newly emerging clones of Bordetella pertussis carrying prn2 and ptxP3 alleles implicated in Australian Pertussis epidemic in 2008-2010. J. Infect. Dis. 205, 1220-1224 (2012
7. Ryan, M. et al. Bordetella pertussis respiratory infection in children is associated with preferential activation of type 1T helper cells. J. Infect. Dis. 175, 1246-1250 (1997
8. Mascart, F. et al. Bordetella pertussis infection in 2-month-old infants promotes type 1T cell responses. J. Immunol. 170, 1504-1509 (2003
9. Mahon, B. P., Sheahan, B. J., Griffi n, F., Murphy, G. & Mills, K. H. Atypical disease after Bordetella pertussis respiratory infection of mice with targeted disruptions of interferon-gamma receptor or immunoglobulin mu chain genes. J. Exp. Med. 186, 1843-1851 (1997
10. Barbic, J., Leef, M. F., Burns, D. L. & Shahin, R. D. Role of gamma interferon in natural clearance of Bordetella pertussis infection. Infect. Immun. 65, 4904-4908 (1997
11. Mills, K. H., Barnard, A., Watkins, J. & Redhead, K. Cell-mediated immunity to Bordetella pertussis: role of Th1 cells in bacterial clearance in a murine respiratory infection model. Infect. Immun. 61, 399-410 (1993
12. Dunne, P. J., Moran, B., Cummins, R. C. & Mills, K. H. CD11c+CD8\{alpha\}+ dendritic cells promote protective immunity to respiratory infection with Bordetella pertussis. J. Immunol. 183, 400-410 (2009
13. Byrne, P., McGuirk, P., Todryk, S. & Mills, K. H. Depletion of NK cells results in disseminating lethal infection with Bordetella pertussis associated with a reduction of antigen-specifi c Th1 and enhancement of Th2, but not Tr1 cells. Eur. J. Immunol. 34, 2579-2588 (2004
14. Ryan, M. et al. Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children. Immunology 93, 1-10 (1998
15. Ausiello, C. M., Urbani, F., la Sala, A., Lande, R. & Cassone, A. Vaccineand antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines. Infect. Immun. 65, 2168-2174 (1997
16. Carbonetti, N. H., Artamonova, G. V., Van Rooijen, N. & Ayala, V. I. Pertussis toxin targets airway macrophages to promote Bordetella pertussis infection of the respiratory tract. Infect. Immun. 75, 1713-1720 (2007
17. Lamberti, Y. A., Hayes, J. A., Perez Vidakovics, M. L., Harvill, E. T. & Rodriguez, M. E. Intracellular traffi cking of Bordetella pertussis in human macrophages. Infect. Immun. 78, 907-913 (2010
18. Paddock, C. D. et al. Pathology and pathogenesis of fatal Bordetella pertussis infection in infants. Clin. Infect. Dis. 47, 328-338 (2008
19. Hellwig, S. M., Hazenbos, W. L., van de Winkel, J. G. & Mooi, F. R. Evidence for an intracellular niche for Bordetella pertussis in bronchoalveolar lavage cells of mice. FEMS Immunol. Med. Microbiol. 26, 203-207 (1999
20. McGuirk, P., Mahon, B. P., Griffi n, F. & Mills, K. H. Compartmentalization of T cell responses following respiratory infection with Bordetella pertussis: hyporesponsiveness of lung T cells is associated with modulated expression of the co-stimulatory molecule CD28. Eur. J. Immunol. 28, 153-163 (1998
21. Bromberg, K., Tannis, G. & Steiner, P. Detection of Bordetella pertussis associated with the alveolar macrophages of children with human immunodefi ciency virus infection. Infect. Immun. 59, 4715-4719 (1991
22. Saukkonen, K., Cabellos, C., Burroughs, M., Prasad, S. & Tuomanen, E. Integrin-mediated localization of Bordetella pertussis within macrophages: role in pulmonary colonization. J. Exp. Med. 173, 1143-1149 (1991
23. Friedman, R. L., Nordensson, K., Wilson, L., Akporiaye, E. T. & Yocum, D. E. Uptake and intracellular survival of Bordetella pertussis in human macrophages. Infect. Immun. 60, 4578-4585 (1992
24. Lamberti, Y. A., Hayes, J. A., Perez Vidakovics, M. L., Harvill, E. T. & Rodriguez, M. E. Intracellular traffi cking of Bordetella pertussis in human macrophages. Infect. Immun. 78, 907-913 (2010
25. Mahon, B. P. & Mills, K. H. Interferon-gamma mediated immune effector mechanisms against Bordetella pertussis. Immunol. Lett. 68, 213-217 (1999
26. Higgins, S. C., Jarnicki, A. G., Lavelle, E. C. & Mills, K. H. TLR4 mediates vaccine-induced protective cellular immunity to Bordetella pertussis: role of IL-17-producing T cells. J. Immunol. 177, 7980-7989 (2006
27. Higgins, S. C. et al. Toll-like receptor 4-mediated innate IL-10 activates antigen-specifi c regulatory T cells and confers resistance to Bordetella pertussis by inhibiting infl ammatory pathology. J. Immunol. 171, 3119-3127 (2003
28. Banus, H. A. et al. Host genetics of Bordetella pertussis infection in mice: signifi cance of Toll-like receptor 4 in genetic susceptibility and pathobiology. Infect. Immun. 74, 2596-2605 (2006
29. Dunne, A. et al. Infl ammasome activation by adenylate cyclase toxin directs Th17 responses and protection against Bordetella pertussis. J. Immunol. 185, 1711-1719 (2010
30. Fedele, G. et al. Bordetella pertussis commits human dendritic cells to promote a Th1/Th17 response through the activity of adenylate cyclase toxin and MAPK-pathways. PLoS One 5, e8734 (2010
31. McGuirk, P., McCann, C. & Mills, K. H. Pathogen-specifi c T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: a novel strategy for evasion of protective T helper type 1 responses by Bordetella pertussis. J. Exp. Med. 195, 221-231 (2002
32. Coleman, M. M. et al. The immunoregulatory role of CD4(+) FoxP3(+) CD25(-) regulatory T cells in lungs of mice infected with Bordetella pertussis. FEMS Immunol. Med. Microbiol. (2011
33. Lamberti, Y., Perez Vidakovics, M. L., van der Pol, L. W. & Rodriguez, M. E. Cholesterol-rich domains are involved in Bordetella pertussis phagocytosis and intracellular survival in neutrophils. Microb. Pathog. 44, 501-511 (2008
34. McGuirk, P. & Mills, K. H. A regulatory role for interleukin 4 in differential infl ammatory responses in the lung following infection of mice primed with Th1- or Th2-inducing pertussis vaccines. Infect. Immun. 68, 1383-1390 (2000
35. Zhang, X., Goel, T., Goodfi eld, L. L., Muse, S. J. & Harvill, E. T. Decreased leukocyte accumulation and delayed Bordetella pertussis clearance in IL-6-/- mice. J. Immunol. 186, 4895-4904 (2011
36. Andreasen, C. & Carbonetti, N. H. Role of neutrophils in response to Bordetella pertussis infection in mice. Infect. Immun. 77, 1182-1188 (2009
37. Confer, D. L. & Eaton, J. W. Pathogen-host jujitsu: phagocyte impotence caused by internalized bacterial adenylate cyclase. Trans. Assoc. Am. Physicians 95, 1-7 (1982
38. Harvill, E. T., Cotter, P. A. & Miller, J. F. Pregenomic comparative analysis between Bordetella bronchiseptica RB50 and Bordetella pertussis tohama I in murine models of respiratory tract infection. Infect. Immun. 67, 6109-6118 (1999
39. Travis, S. M., Singh, P. K. & Welsh, M. J. Antimicrobial peptides and proteins in the innate defense of the airway surface. Curr. Opin. Immunol. 13, 89-95 (2001
40. Fernandez, R. C. & Weiss, A. A. Susceptibilities of Bordetella pertussis strains to antimicrobial peptides. Antimicrob. Agents Chemother. 40, 1041-1043 (1996
41. Elahi, S. et al. The host defense peptide beta-defensin 1 confers protection against Bordetella pertussis in newborn piglets. Infect. Immun. 74, 2338-2352 (2006
42. Erles, K. & Brownlie, J. Expression of beta-defensins in the canine respiratory tract and antimicrobial activity against Bordetella bronchiseptica. Vet. Immunol. Immunopathol. 135, 12-19 (2010
43. Elahi, S. et al. Infection with Bordetella parapertussis but not Bordetella pertussis causes pertussis-like disease in older pigs. J. Infect. Dis. 198, 384-392 (2008
44. Legarda, D., Klein-Patel, M. E., Yim, S., Yuk, M. H. & Diamond, G. Suppression of NF-kappaB-mediated beta-defensin gene expression in the mammalian airway by the Bordetella type III secretion system. Cell Microbiol. 7, 489-497 (2005
45. Kao, C. Y. et al. IL-17 markedly up-regulates beta-defensin-2 expression in human airway epithelium via JAK and NF-kappaB signaling pathways. J. Immunol. 173, 3482-3491 (2004
46. Fernandez, R. C. & Weiss, A. A. Cloning and sequencing of a Bordetella pertussis serum resistance locus. Infect. Immun. 62, 4727-4738 (1994
47. Barnes, M. G. & Weiss, A. A. BrkA protein of Bordetella pertussis inhibits the classical pathway of complement after C1 deposition. Infect. Immun. 69, 3067-3072 (2001
48. Weiss, A. A., Mobberley, P. S., Fernandez, R. C. & Mink, C. M. Characterization of human bactericidal antibodies to Bordetella pertussis. Infect. Immun. 67, 1424-1431 (1999
49. Barnes, M. G. & Weiss, A. A. Growth phase infl uences complement resistance of Bordetella pertussis. Infect. Immun. 70, 403-406 (2002
50. Pishko, E. J., Betting, D. J., Hutter, C. S. & Harvill, E. T. Bordetella pertussis acquires resistance to complement-mediated killing in vivo. Infect. Immun. 71, 4936-4942 (2003
51. Goebel, E. M., Wolfe, D. N., Elder, K., Stibitz, S. & Harvill, E. T. O antigen protects Bordetella parapertussis from complement. Infect. Immun. 76, 1774-1780 (2008
52. Berggard, K., Johnsson, E., Mooi, F. R. & Lindahl, G. Bordetella pertussis binds the human complement regulator C4BP: role of fi lamentous hemagglutinin. Infect. Immun. 65, 3638-3643 (1997
53. Marr, N., Luu, R. A. & Fernandez, R. C. Bordetella pertussis binds human C1 esterase inhibitor during the virulent phase, to evade complementmediated killing. J. Infect. Dis. 195, 585-588 (2007
54. Barnes, M. G. & Weiss, A. A. Activation of the complement cascade by Bordetella pertussis. FEMS Microbiol. Lett. 220, 271-275 (2003
55. Amdahl, H. et al. Interactions between Bordetella pertussis and the complement inhibitor factor H. Mol. Immunol. 48, 697-705 (2011
56. Hellwig, S. M., van Spriel, A. B., Schellekens, J. F., Mooi, F. R. & van de Winkel, J. G. Immunoglobulin A-mediated protection against Bordetella pertussis infection. Infect. Immun. 69, 4846-4850 (2001
57. Quinello, C., Quintilio, W., Carneiro-Sampaio, M. & Palmeira, P. Passive acquisition of protective antibodies reactive with Bordetella pertussis in newborns via placental transfer and breast-feeding. Scand. J. Immunol. 72, 66-73 (2010
58. Mills, K. H. Immunity to Bordetella pertussis. Microbes Infect. 3, 655-677 (2001
59. Mielcarek, N. et al. Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough. PLoS Pathog. 2, e65 (2006
60. Granstrom, M., Olinder-Nielsen, A. M., Holmblad, P., Mark, A. & Hanngren, K. Specifi c immunoglobulin for treatment of whooping cough. Lancet 338, 1230-1233 (1991
61. Simondon, F. et al. A randomized double-blind trial comparing a twocomponent acellular to a whole-cell pertussis vaccine in Senegal. Vaccine 15, 1606-1612 (1997
62. Olin, P., Rasmussen, F., Gustafsson, L., Hallander, H. O. & Heijbel, H. Randomised controlled trial of two-component, three-component, and fi ve-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet 350, 1569-1577 (1997
63. Greco, D. et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. N. Engl. J. Med. 334, 341-348 (1996
64. Gustafsson, L., Hallander, H. O., Olin, P., Reizenstein, E. & Storsaeter, J. A controlled trial of a two-component acellular, a fi ve-component acellular, and a whole-cell pertussis vaccine. N. Engl. J. Med. 334, 349-355 (1996
65. Trollfors, B. et al. A placebo-controlled trial of a pertussis-toxoid vaccine. N. Engl. J. Med. 333, 1045-1050 (1995
66. Storsaeter, J., Hallander, H. O., Gustafsson, L. & Olin, P. Levels of antipertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 16, 1907-1916 (1998
67. Cherry, J. D., Gornbein, J., Heininger, U. & Stehr, K. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 16, 1901-1906 (1998
68. Taranger, J. et al. Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis. J. Infect. Dis. 181, 1010-1013 (2000
69. Giuliano, M. et al. Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis. J. Pediatr. 132, 983-988 (1998
70. Salmaso, S. et al. Persistence of protection through 33 months of age provided by immunization in infancy with two three-component acellular pertussis vaccines. Stage II Working Group. Vaccine 16, 1270-1275 (1998
71. Hendrikx, L. H. et al. Enhanced memory B-cell immune responses after a second acellular pertussis booster vaccination in children 9 years of age. Vaccine 30, 51-58 (2011
72. Mahon, B. P., Brady, M. T. & Mills, K. H. Protection against Bordetella pertussis in mice in the absence of detectable circulating antibody: implications for long-term immunity in children. J. Infect. Dis. 181, 2087-2091 (2000
73. Mills, K. H., Ryan, M., Ryan, E. & Mahon, B. P. A murine model in which protection correlates with pertussis vaccine effi cacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis. Infect. Immun. 66, 594-602 (1998
74. Leef, M., Elkins, K. L., Barbic, J. & Shahin, R. D. Protective immunity to Bordetella pertussis requires both B cells and CD4(+) T cells for key functions other than specifi c antibody production. J. Exp. Med. 191, 1841-1852 (2000
75. Shahin, R. D., Witvliet, M. H. & Manclark, C. R. Mechanism of pertussis toxin B oligomer-mediated protection against Bordetella pertussis respiratory infection. Infect. Immun. 58, 4063-4068 (1990
76. Golovkina, T. V., Shlomchik, M., Hannum, L. & Chervonsky, A. Organogenic role of B lymphocytes in mucosal immunity. Science 286, 1965-1968 (1999
77. Mosmann, T. R., Cherwinski, H., Bond, M. W., Giedlin, M. A. & Coffman, R. L. Two types of murine helper T cell clone. I. Defi nition according to profi les of lymphokine activities and secreted proteins. J. Immunol. 136, 2348-2357 (1986
78. Sakaguchi, S., Fukuma, K., Kuribayashi, K. & Masuda, T. Organ-specifi c autoimmune diseases induced in mice by elimination of T cell subset. I. Evidence for the active participation of T cells in natural self-tolerance; defi cit of a T cell subset as a possible cause of autoimmune disease. J Exp. Med. 161, 72-87 (1985
79. Langrish, C. L. et al. IL-23 drives a pathogenic T cell population that induces autoimmune infl ammation. J. Exp. Med. 201, 233-240 (2005
80. De Magistris, M. T., Romano, M., Bartoloni, A., Rappuoli, R. & Tagliabue, A. Human T cell clones defi ne S1 subunit as the most immunogenic moiety of pertussis toxin and determine its epitope map. J. Exp. Med. 169, 1519-1532 (1989
81. Hafl er, J. P. & Pohl-Koppe, A. The cellular immune response to Bordetella pertussis in two children with whooping cough. Eur. J. Med. Res. 3, 523-526 (1998
82. Peppoloni, S. et al. Lymphokine secretion and cytotoxic activity of human CD4+ T-cell clones against Bordetella pertussis. Infect. Immun. 59, 3768-3773 (1991
83. Tran Minh, N. N. et al. Cell-mediated immune responses to antigens of Bordetella pertussis and protection against pertussis in school children. Pediatr. Infect. Dis. J. 18, 366-370 (1999
84. Ausiello, C. M., Lande, R., la Sala, A., Urbani, F. & Cassone, A. Cellmediated immune response of healthy adults to Bordetella pertussis vaccine antigens. J. Infect. Dis. 178, 466-470 (1998
85. Fennelly, N. K. et al. Bordetella pertussis expresses a functional type III secretion system that subverts protective innate and adaptive immune responses. Infect. Immun. 76, 1257-1266 (2008
86. Cua, D. J. & Tato, C. M. Innate IL-17-producing cells: The sentinels of the immune system. Nat. Rev. Immunol. 10, 479-489 (2010
87. Agarwal, S. K. et al. Association of interleukin 23 receptor polymorphisms with anti-topoisomerase-I positivity and pulmonary hypertension in systemic sclerosis. J. Rheumatol. 36, 2715-2723 (2009
88. Zepp, F. et al. Pertussis-specifi c cell-mediated immunity in infants after vaccination with a tricomponent acellular pertussis vaccine. Infect. Immun. 64, 4078-4084 (1996
89. White, O. J. et al. Th2-polarisation of cellular immune memory to neonatal pertussis vaccination. Vaccine 28, 2648-2652 (2010
90. Ryan, E. J., Nilsson, L., Kjellman, N., Gothefors, L. & Mills, K. H. Booster immunization of children with an acellular pertussis vaccine enhances Th2 cytokine production and serum IgE responses against pertussis toxin but not against common allergens. Clin. Exp. Immunol. 121, 193-200 (2000
91. Ausiello, C. M. et al. Cell-mediated immune responses in four-year-old children after primary immunization with acellular pertussis vaccines. Infect. Immun. 67, 4064-4071 (1999
92. Skowronski, D. M. et al. Injection-site reactions to booster doses of acellular pertussis vaccine: rate, severity, and anticipated impact. Pediatrics 112, e453 (2003
93. Zachariadis, O., Cassidy, J. P., Brady, J. & Mahon, B. P. gammadelta T cells regulate the early infl ammatory response to Bordetella pertussis infection in the murine respiratory tract. Infect. Immun. 74, 1837-1845 (2006
94. Mahon, B. P., Ryan, M. S., Griffi n, F. & Mills, K. H. Interleukin-12 is produced by macrophages in response to live or killed Bordetella pertussis and enhances the effi cacy of an acellular pertussis vaccine by promoting induction of Th1 cells. Infect. Immun. 64, 5295-5301 (1996
95. Torre, D., Ferrario, G., Bonetta, G., Perversi, L. & Speranza, F. In vitro and in vivo induction of nitric oxide by murine macrophages stimulated with Bordetella pertussis. FEMS Immunol. Med. Microbiol. 13, 95-99 (1996
96. Canthaboo, C., Xing, D., Wei, X. Q. & Corbel, M. J. Investigation of role of nitric oxide in protection from Bordetella pertussis respiratory challenge. Infect. Immun. 70, 679-684 (2002
97. Andreasen, C., Powell, D. A. & Carbonetti, N. H. Pertussis toxin stimulates IL-17 production in response to Bordetella pertussis infection in mice. PLoS One 4, e7079 (2009
98. Kirimanjeswara, G. S., Agosto, L. M., Kennett, M. J., Bjornstad, O. N. & Harvill, E. T. Pertussis toxin inhibits neutrophil recruitment to delay antibody-mediated clearance of Bordetella pertussis. J. Clin. Invest. 115, 3594-3601 (2005
99. Redhead, K., Watkins, J., Barnard, A. & Mills, K. H. Effective immunization against Bordetella pertussis respiratory infection in mice is dependent on induction of cell-mediated immunity. Infect. Immun. 61, 3190-3198 (1993
100. Barnard, A., Mahon, B. P., Watkins, J., Redhead, K. & Mills, K. H. Th1/Th2 cell dichotomy in acquired immunity to Bordetella pertussis: variables in the in vivo priming and in vitro cytokine detection techniques affect the classifi cation of T-cell subsets as Th1, Th2 or Th0. Immunology. 87, 372-380 (1996
101. Ryan, M., Gothefors, L., Storsaeter, J. & Mills, K. H. Bordetella pertussis -specifi c Th1/Th2 cells generated following respiratory infection or immunization with an acellular vaccine: comparison of the T cell cytokine profi les in infants and mice. Dev. Biol. Stand. 89, 297-305 (1997
102. Mills, K. H. & Redhead, K. Cellular immunity in pertussis. J. Med. Microbiol. 39, 163-164 (1993
103. Brereton, C. F. et al. Escherichia coli heat-labile enterotoxin promotes protective Th17 responses against infection by driving innate IL-1 and IL-23 production. J. Immunol. 186, 5896-5906 (2011).
104. Mills, K. H. Regulatory T cells: friend or foe in immunity to infection? Nat. Rev. Immunol. 4, 841-855 (2004
105. McGuirk, P. & Mills, K. H. Pathogen-specifi c regulatory T cells provoke a shift in the Th1/Th2 paradigm in immunity to infectious diseases. Trends Immunol. 23, 450-455 (2002
106. McGuirk, P. & Mills, K. H. Direct anti-infl ammatory effect of a bacterial virulence factor: IL-10-dependent suppression of IL-12 production by fi lamentous hemagglutinin from Bordetella pertussis. Eur. J. Immunol. 30, 415-422 (2000
107. Ross, P. J., Lavelle, E. C., Mills, K. H. & Boyd, A. P. Adenylate cyclase toxin from Bordetella pertussis synergizes with lipopolysaccharide to promote innate interleukin-10 production and enhances the induction of Th2 and regulatory T cells. Infect. Immun. 72, 1568-1579 (2004
108. Boyd, A. P. et al. Bordetella pertussis adenylate cyclase toxin modulates innate and adaptive immune responses: distinct roles for acylation and enzymatic activity in immunomodulation and cell death. J. Immunol. 175, 730-738 (2005
109. Nagamatsu, K. et al. Bordetella evades the host immune system by inducing IL-10 through a type III effector, BopN. J. Exp. Med. 206, 3073-3088 (2009
110. Skinner, J. A., Reissinger, A., Shen, H. & Yuk, M. H. Bordetella type III secretion and adenylate cyclase toxin synergize to drive dendritic cells into a semimature state. J. Immunol. 173, 1934-1940 (2004
111. Cotter, P. A. & DiRita, V. J. Bacterial virulence gene regulation: An evolutionary perspective. Annu. Rev. Microbiol. 54, 519-565 (2000
112. Locht, C., Bertin, P., Menozzi, F. D. & Renauld, G. The fi lamentous haemagglutinin, a multifaceted adhesion produced by virulent Bordetella spp. Mol. Microbiol. 9, 653-660 (1993
113. de Gouw, D., Diavatopoulos, D. A., Bootsma, H. J., Hermans, P. W. & Mooi, F. R. Pertussis: A matter of immune modulation. FEMS Microbiol. Rev. 35, 441-474 (2011
114. Perez Vidakovics, M. L., Lamberti, Y., van der Pol, W. L., Yantorno, O. & Rodriguez, M. E. Adenylate cyclase infl uences fi lamentous haemagglutinin-mediated attachment of Bordetella pertussis to epithelial alveolar cells. FEMS Immunol. Med. Microbiol. 48, 140-147 (2006
115. Lamberti, Y., Alvarez Hayes, J., Perez Vidakovics, M. L. & Rodriguez, M. E. Cholesterol-dependent attachment of human respiratory cells by Bordetella pertussis. FEMS Immunol. Med. Microbiol. 56, 143-150 (2009
116. Ishibashi, Y. & Nishikawa, A. Bordetella pertussis infection of human respiratory epithelial cells up-regulates intercellular adhesion molecule-1 expression: role of fi lamentous hemagglutinin and pertussis toxin. Microb. Pathog. 33, 115-125 (2002
117. Mobberley-Schuman, P. S., Connelly, B. & Weiss, A. A. Phagocytosis of Bordetella pertussis incubated with convalescent serum. J. Infect. Dis. 187, 1646-1653 (2003
118. Relman, D. et al. Recognition of a bacterial adhesion by an integrin: macrophage CR3 (alpha M beta 2, CD11b/CD18) binds fi lamentous hemagglutinin of Bordetella pertussis. Cell 61, 1375-1382 (1990
119. Dirix, V. et al. Monocyte-derived interleukin-10 depresses the Bordetella pertussis-specifi c gamma interferon response in vaccinated infants. Clin. Vaccine Immunol. 16, 1816-1821 (2009
120. Abramson, T., Kedem, H. & Relman, D. A. Modulation of the NF-kappaB pathway by Bordetella pertussis fi lamentous hemagglutinin. PLoS One 3, e3825 (2008
121. Dieterich, C. & Relman, D. A. Modulation of the host interferon response and ISGylation pathway by B. pertussis fi lamentous hemagglutinin. PLoS One 6, e27535 (2011
122. Lobet, Y. et al. Site-specifi c alterations in the B oligomer that affect receptor-binding activities and mitogenicity of pertussis toxin. J. Exp. Med. 177, 79-87 (1993
123. van't Wout, J. et al. Role of carbohydrate recognition domains of pertussis toxin in adherence of Bordetella pertussis to human macrophages. Infect. Immun. 60, 3303-3308 (1992
124. Saukkonen, K., Burnette, W. N., Mar, V. L., Masure, H. R. & Tuomanen, E. I. Pertussis toxin has eukaryotic-like carbohydrate recognition domains. Proc. Natl. Acad. Sci. USA. 89, 118-122 (1992
125. Ryan, M., McCarthy, L., Rappuoli, R., Mahon, B. P. & Mills, K. H. Pertussis toxin potentiates Th1 and Th2 responses to co-injected antigen: Adjuvant action is associated with enhanced regulatory cytokine production and expression of the co-stimulatory molecules B7-1, B7-2 and CD28. Int. Immunol. 10, 651-662 (1998
126. Carbonetti, N. H. Pertussis toxin and adenylate cyclase toxin: key virulence factors of Bordetella pertussis and cell biology tools. Future Microbiol. 5, 455-469 (2010
127. Shumilla, J. A. et al. Bordetella pertussis infection of primary human monocytes alters HLA-DR expression. Infect. Immun. 72, 1450-1462 (2004
128. Martino, A., Volpe, E., Auricchio, G., Colizzi, V. & Baldini, P. M. Infl uence of pertussis toxin on CD1a isoform expression in human dendritic cells. J. Clin. Immunol. 26, 153-159 (2006
129. Schneider, O. D., Weiss, A. A. & Miller, W. E. Pertussis toxin utilizes proximal components of the T-cell receptor complex to initiate signal transduction events in T cells. Infect. Immun. 75, 4040-4049 (2007
130. Schneider, O. D., Weiss, A. A. & Miller, W. E. Pertussis toxin signals through the TCR to initiate cross-desensitization of the chemokine receptor CXCR4. J. Immunol. 182, 5730-5739 (2009
131. Carbonetti, N. H. et al. Suppression of serum antibody responses by pertussis toxin after respiratory tract colonization by Bordetella pertussis and identifi cation of an immunodominant lipoprotein. Infect. Immun. 72, 3350-3358 (2004
132. Mielcarek, N. et al. Homologous and heterologous protection after single intranasal administration of live attenuated recombinant Bordetella pertussis. Nat. Biotechnol. 16, 454-457 (1998
133. Andreasen, C. & Carbonetti, N. H. Pertussis toxin inhibits early chemokine production to delay neutrophil recruitment in response to Bordetella pertussis respiratory tract infection in mice. Infect. Immun. 76, 5139-5148 (2008
134. Ayala, V. I., Teijaro, J. R., Farber, D. L., Dorsey, S. G. & Carbonetti, N. H. Bordetella pertussis infection exacerbates infl uenza virus infection through pertussis toxin-mediated suppression of innate immunity. PLoS One 6, e19016 (2011
135. Hofstetter, H. H., Shive, C. L. & Forsthuber, T. G. Pertussis toxin modulates the immune response to neuroantigens injected in incomplete Freund's adjuvant: induction of Th1 cells and experimental autoimmune encephalomyelitis in the presence of high frequencies of Th2 cells. J. Immunol. 169, 117-125 (2002
136. Hou, W. et al. Pertussis toxin enhances Th1 responses by stimulation of dendritic cells. J. Immunol. 170, 1728-1736 (2003
137. Chen, X., Howard, O. M. & Oppenheim, J. J. Pertussis toxin by inducing IL-6 promotes the generation of IL-17-producing CD4 cells. J. Immunol. 178, 6123-6129 (2007
138. Cassan, C. et al. Pertussis toxin reduces the number of splenic Foxp3+regulatory T cells. J. Immunol. 177, 1552-1560 (2006
139. Chen, X. et al. Pertussis toxin as an adjuvant suppresses the number and function of CD4+CD25+ T regulatory cells. Eur. J. Immunol. 36, 671-680 (2006
140. Weber, M. S. et al. Repetitive pertussis toxin promotes development of regulatory T cells and prevents central nervous system autoimmune disease. PLoS One 5, e16009 (2010
141. Everest, P. et al. Role of the Bordetella pertussis P.69/pertactin protein and the P.69/pertactin RGD motif in the adherence to and invasion of mammalian cells. Microbiology 142 (Pt 11), 3261-3268 (1996
142. Charles, I. G. et al. Molecular cloning and characterization of protective outer membrane protein P.69 from Bordetella pertussis. Proc. Natl. Acad. Sci. USA. 86, 3554-3558 (1989
143. Ruoslahti, E. RGD and other recognition sequences for integrins. Annu. Rev. Cell Dev. Biol. 12, 697-715 (1996
144. Inatsuka, C. S. et al. Pertactin is required for Bordetella species to resist neutrophil-mediated clearance. Infect. Immun. 78, 2901-2909 (2010
145. Roberts, M. et al. Construction and characterization of Bordetella pertussis mutants lacking the vir-regulated P.69 outer membrane protein. Mol. Microbiol. 5, 1393-1404 (1991
146. Novotny, P., Chubb, A. P., Cownley, K. & Charles, I. G. Biologic and protective properties of the 69-kDa outer membrane protein of Bordetella pertussis: A novel formulation for an acellular pertussis vaccine. J. Infect. Dis. 164, 114-122 (1991
147. Hijnen, M. et al. Epitope structure of the Bordetella pertussis protein P.69 pertactin, a major vaccine component and protective antigen. Infect. Immun. 72, 3716-3723 (2004
148. Guermonprez, P. et al. The adenylate cyclase toxin of Bordetella pertussis binds to target cells via the alpha(M)beta(2) integrin (CD11b/CD18). J. Exp. Med. 193, 1035-1044 (2001
149. Eby, J. C., Gray, M. C., Mangan, A. R., Donato, G. M. & Hewlett, E. L. Role of CD11b/CD18 in the process of intoxication by the Adenylate cyclase toxin of Bordetella pertussis. Infect. Immun. 80, 850-859 (2012
150. Khelef, N. & Guiso, N. Induction of macrophage apoptosis by Bordetella pertussis adenylate cyclase-hemolysin. FEMS Microbiol. Lett. 134, 27-32 (1995
151. Gray, M. C. & Hewlett, E. L. Cell cycle arrest induced by the bacterial adenylate cyclase toxins from Bacillus anthracis and Bordetella pertussis. Cell. Microbiol. 13, 123-134 (2011
152. Kamanova, J. et al. Adenylate cyclase toxin subverts phagocyte function by RhoA inhibition and unproductive ruffl ing. J. Immunol. 181, 5587-5597 (2008
153. Bagley, K. C., Abdelwahab, S. F., Tuskan, R. G., Fouts, T. R. & Lewis, G. K. Pertussis toxin and the adenylate cyclase toxin from Bordetella pertussis activate human monocyte-derived dendritic cells and dominantly inhibit cytokine production through a cAMP-dependent pathway. J. Leukoc. Biol. 72, 962-969 (2002
154. Hickey, F. B., Brereton, C. F. & Mills, K. H. Adenylate cycalse toxin of Bordetella pertussis inhibits TLR-induced IRF-1 and IRF-8 activation and IL-12 production and enhances IL-10 through MAPK activation in dendritic cells. J. Leukoc. Biol. 84, 234-243 (2008
155. Spensieri, F. et al. Bordetella pertussis inhibition of interleukin-12 (IL-12) p70 in human monocyte-derived dendritic cells blocks IL-12 p35 through adenylate cyclase toxin-dependent cyclic AMP induction. Infect. Immun. 74, 2831-2838 (2006
156. Perkins, D. J., Gray, M. C., Hewlett, E. L. & Vogel, S. N. Bordetella pertussis adenylate cyclase toxin (ACT) induces cyclooxygenase-2 (COX-2) in murine macrophages and is facilitated by ACT interaction with CD11b/CD18 (Mac-1). Mol. Microbiol. 66, 1003-1015 (2007
157. Gray, M., Szabo, G., Otero, A. S., Gray, L. & Hewlett, E. Distinct mechanisms for K+ effl ux, intoxication, and hemolysis by Bordetella pertussis AC toxin. J. Biol. Chem. 273, 18260-18267 (1998
158. Cheung, G. Y. et al. Effect of different forms of adenylate cyclase toxin of Bordetella pertussis on protection afforded by an acellular pertussis vaccine in a murine model. Infect. Immun. 74, 6797-6805 (2006
159. Betsou, F., Sebo, P. & Guiso, N. The C-terminal domain is essential for protective activity of the Bordetella pertussis adenylate cyclasehemolysin. Infect. Immun. 63, 3309-3315 (1995
160. Preston, A. et al. Genetic basis for lipopolysaccharide O-antigen biosynthesis in Bordetellae. Infect. Immun. 67, 3763-3767 (1999
161. Harvill, E. T. et al. Multiple roles for Bordetella lipopolysaccharide molecules during respiratory tract infection. Infect. Immun. 68, 6720-6728 (2000
162. Preston, A. & Maskell, D. The molecular genetics and role in infection of lipopolysaccharide biosynthesis in the Bordetellae. J. Endotoxin Res. 7, 251-261 (2001
163. Errea, A. et al. Mucosal innate response stimulation induced by lipopolysaccharide protects against Bordetella pertussis colonization. Med. Microbiol. Immunol. 199, 103-108 (2010
164. Schaeffer, L. M., McCormack, F. X., Wu, H. & Weiss, A. A. Bordetella pertussis lipopolysaccharide resists the bactericidal effects of pulmonary surfactant protein A. J. Immunol. 173, 1959-1965 (2004
165. Loscher, C. E., Donnelly, S., McBennett, S., Lynch, M. A. & Mills, K. H. Proinfl ammatory cytokines in the adverse systemic and neurologic effects associated with parenteral injection of a whole cell pertussis vaccine. Ann. NY Acad. Sci. 856, 274-277 (1998
166. Loscher, C. E., Donnelly, S., Mills, K. H. & Lynch, M. A. Interleukin-1betadependent changes in the hippocampus following parenteral immunization with a whole cell pertussis vaccine. J. Neuroimmunol. 111, 68-76 (2000
167. Donnelly, S., Loscher, C. E., Lynch, M. A. & Mills, K. H. Whole-cell but not acellular pertussis vaccines induce convulsive activity in mice: evidence of a role for toxin-induced interleukin-1beta in a new murine model for analysis of neuronal side effects of vaccination. Infect. Immun. 69, 4217-4223 (2001
168. Bannatyne, R. M. & Jackowski, J. Protective effectiveness of an endotoxin-depleted pertussis vaccine. Vaccine 5, 268-269 (1987
169. Cookson, B. T., Cho, H. L., Herwaldt, L. A. & Goldman, W. E. Biological activities and chemical composition of purifi ed tracheal cytotoxin of Bordetella pertussis. Infect. Immun. 57, 2223-2229 (1989
170. Magalhaes, J. G. et al. Murine Nod1 but not its human orthologue mediates innate immune detection of tracheal cytotoxin. EMBO Rep. 6, 1201-1207 (2005
171. Kaneko, T. et al. Monomeric and polymeric gram-negative peptidoglycan but not purifi ed LPS stimulate the Drosophila IMD pathway. Immunity 20, 637-649 (2004
172. Cookson, B. T., Tyler, A. N. & Goldman, W. E. Primary structure of the peptidoglycan-derived tracheal cytotoxin of Bordetella pertussis. Biochemistry 28, 1744-1749 (1989
173. Heiss, L. N., Flak, T. A., Lancaster, J. R. Jr., McDaniel, M. L. & Goldman, W. E. Nitric oxide mediates Bordetella pertussis tracheal cytotoxin damage to the respiratory epithelium. Infect. Agents Dis. 2, 173-177 (1993
174. Flak, T. A., Heiss, L. N., Engle, J. T. & Goldman, W. E. Synergistic epithelial responses to endotoxin and a naturally occurring muramyl peptide. Infect. Immun. 68, 1235-1242 (2000
175. Cundell, D. R. et al. Effect of tracheal cytotoxin from Bordetella pertussis on human neutrophil function in vitro. Infect. Immun. 62, 639-643 (1994
176. Cornelis, G. R. The type III secretion injectisome. Nat. Rev. Microbiol. 4, 811-825 (2006
177. Kerr, J. R., Rigg, G. P., Matthews, R. C. & Burnie, J. P. The Bpel locus encodes type III secretion machinery in Bordetella pertussis. Microb. Pathog. 27, 349-367 (1999
178. Fauconnier, A. et al. Characterization of the type III secretion locus of Bordetella pertussis. Int. J. Med. Microbiol. 290, 693-705 (2001
179. Mattoo, S., Yuk, M. H., Huang, L. L. & Miller, J. F. Regulation of type III secretion in Bordetella. Mol. Microbiol. 52, 1201-1214 (2004
180. Han, H. J., Kuwae, A., Abe, A., Arakawa, Y. & Kamachi, K. Differential expression of type III effector BteA protein due to IS481 insertion in Bordetella pertussis. PLoS One 6, e17797 (2011
181. Kuwae, A. et al. BopC is a novel type III effector secreted by Bordetella bronchiseptica and has a critical role in type III-dependent necrotic cell death. J. Biol. Chem. 281, 6589-6600 (2006
182. Gaillard, M. E., Bottero, D., Castuma, C. E., Basile, L. A. & Hozbor, D. Laboratory adaptation of Bordetella pertussis is associated with the loss of type three secretion system functionality. Infect. Immun. 79, 3677-3682 (2011
183. Hallander, H. O., Advani, A., Donnelly, D., Gustafsson, L. & Carlsson, R. M. Shifts of Bordetella pertussis variants in Sweden from 1970 to 2003, during three periods marked by different vaccination programs. J. Clin. Microbiol. 43, 2856-2865 (2005
184. Mooi, F. R. et al. Bordetella pertussis strains with increased toxin production associated with pertussis resurgence. Emerg. Infect. Dis. 15, 1206-1213 (2009
185. Jarnicki, A. G. et al. Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their effi cacy as vaccine adjuvants and cancer immunotherapeutics. J. Immunol. 180, 3797-3806 (2008
186. Sugai, T. et al. A CpG-containing oligodeoxynucleotide as an effi cient adjuvant counterbalancing the Th1/Th2 immune response in diphtheria-tetanus- pertussis vaccine. Vaccine 23, 5450-5456 (2005
187. Marr, N. et al. Protective activity of the Bordetella pertussis BrkA autotransporter in the murine lung colonization model. Vaccine 26, 4306-4311 (2008